The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).

Taiga Nishihori,Qaiser Bashir,Marcelo C. Pasquini,Michael Martens,Juan Wu,Melissa Alsina,Yvonne A. Efebera,Cristina Gasparetto,Nancy L. Geller,Sergio Giralt,John Koreth,Philip L. McCarthy,Emma C. Scott,Edward A. Stadtmauer,David H. Vesole,Parameswaran Hari

The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).

2021

Taiga Nishihori
Qaiser Bashir
Marcelo C. Pasquini
Michael Martens
Juan Wu
Melissa Alsina
Yvonne A. Efebera
Cristina Gasparetto
Nancy L. Geller
Sergio Giralt
John Koreth
Philip L. McCarthy
Emma C. Scott
Edward A. Stadtmauer
David H. Vesole
Parameswaran Hari

7003Background: The role of alloHCT and subsequent maintenance for the treatment of high-risk MM has not been fully defined. We evaluated the efficacy of ixazomib maintenance therapy after alloHCT ...

Keywords:

bone transplantation
Placebo-controlled study
Internal medicine
Maintenance therapy
Medicine
Oncology
double blind
Ixazomib
Transplantation
Clinical trial
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations